Cite
HARVARD Citation
Streicher, K. et al. (2018). Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI‐551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease. Arthritis & rheumatology. 70 (12), pp. 2087-2095. [Online].